论文部分内容阅读
目的评价阿糖胞苷+阿克拉霉素+粒细胞集落刺激因子(CAG)与高三尖杉酯碱+阿糖胞苷+粒细胞集落刺激因子(HAG)方案治疗初治老年急性髓系白血病(AML)的疗效及安全性。方法老年AML患者共40例,随机分成CAG组和HAG组,每组20例。分别给予CAG和HAG方案,比较两组化疗的疗效和安全性。结果 CAG组CR所占的比例(65.00%)和有效率(90.00%)均明显高于HAG组(40.00%、60.00%);NR所占的比例(10.00%)明显低于HAG组(40.00%),差异具有统计学意义(P<0.05);CAG和HAG并发症及不良反均差不多,差异无统计学意义(P>0.05)。结论与HAG相比,CAG方案的疗效好、副作用轻,适于在临床推广。
Objective To evaluate the efficacy of cytarabine + aclacinomycin + granulocyte colony stimulating factor (CAG) and homoharringtonine + cytarabine + granulocyte colony stimulating factor (HAG) in the treatment of newly diagnosed acute myeloid leukemia AML) efficacy and safety. Methods Aged 40 elderly patients with AML were randomly divided into CAG group and HAG group, 20 cases in each group. CAG and HAG were given to compare the efficacy and safety of two groups of chemotherapy. Results The proportion of CR (65.00%) and effective rate (90.00%) in CAG group was significantly higher than that in HAG group (40.00%, 60.00%). The proportion of NR in CAG group was significantly lower than that in HAG group (40.00% ), The difference was statistically significant (P <0.05); CAG and HAG complications and adverse reactions were similar, the difference was not statistically significant (P> 0.05). Conclusion Compared with HAG, CAG regimen has good curative effect and light side effect, which is suitable for clinical application.